Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

LDL cholesterol: controversies and future therapeutic directions
Paul M. Ridker
The Lancet (2014) Vol. 384, Iss. 9943, pp. 607-617
Closed Access | Times Cited: 247

Showing 1-25 of 247 citing articles:

Strategies to increase nitric oxide signalling in cardiovascular disease
Jon O. Lundberg, Mark T. Gladwin, Eddie Weitzberg
Nature Reviews Drug Discovery (2015) Vol. 14, Iss. 9, pp. 623-641
Closed Access | Times Cited: 505
Saturated Fat Consumption and Risk of Coronary Heart Disease and Ischemic Stroke: A Science Update
Joyce A. Nettleton, Ingeborg A. Brouwer, Johanna M. Geleijnse, et al.
Annals of Nutrition and Metabolism (2017) Vol. 70, Iss. 1, pp. 26-33
Open Access | Times Cited: 486
Effects of aerobic exercise on lipids and lipoproteins
Yating Wang, Danyan Xu
Lipids in Health and Disease (2017) Vol. 16, Iss. 1
Open Access | Times Cited: 357
Effects of Vegetarian Diets on Blood Lipids: A Systematic Review and Meta‐Analysis of Randomized Controlled Trials
Fenglei Wang, Ju‐Sheng Zheng, Bo Yang, et al.
Journal of the American Heart Association (2015) Vol. 4, Iss. 10
Open Access | Times Cited: 294
Dyslipidemia and cardiovascular disease risk among the MASHAD study population
Mahshad Hedayatnia, Zahra Asadi, Reza Zare‐Feyzabadi, et al.
Lipids in Health and Disease (2020) Vol. 19, Iss. 1
Open Access | Times Cited: 288
Causal associations of blood lipids with risk of ischemic stroke and intracerebral hemorrhage in Chinese adults
Luanluan Sun, Robert Clarke, Derrick Bennett, et al.
Nature Medicine (2019) Vol. 25, Iss. 4, pp. 569-574
Open Access | Times Cited: 263
Pathophysiological mechanisms of increased cardiometabolic risk in people with schizophrenia and other severe mental illnesses
David C. Henderson, Brenda Vincenzi, Norte García Andrea, et al.
The Lancet Psychiatry (2015) Vol. 2, Iss. 5, pp. 452-464
Closed Access | Times Cited: 250
Quantifying Atherogenic Lipoproteins: Current and Future Challenges in the Era of Personalized Medicine and Very Low Concentrations of LDL Cholesterol. A Consensus Statement from EAS and EFLM
Michel R. Langlois, M. John Chapman, Christa M. Cobbaert, et al.
Clinical Chemistry (2018) Vol. 64, Iss. 7, pp. 1006-1033
Open Access | Times Cited: 225
Quantitative Lipoprotein Subclass and Low Molecular Weight Metabolite Analysis in Human Serum and Plasma by 1H NMR Spectroscopy in a Multilaboratory Trial
Beatriz Jiménez, Elaine Holmes, Clement Heude, et al.
Analytical Chemistry (2018) Vol. 90, Iss. 20, pp. 11962-11971
Open Access | Times Cited: 191
Metabolomic Profiling of Statin Use and Genetic Inhibition of HMG-CoA Reductase
Peter Würtz, Qin Wang, Pasi Soininen, et al.
Journal of the American College of Cardiology (2016) Vol. 67, Iss. 10, pp. 1200-1210
Open Access | Times Cited: 186
Apolipoprotein B and Cardiovascular Disease: Biomarker and Potential Therapeutic Target
Jennifer Behbodikhah, Saba Ahmed, Ailin Elyasi, et al.
Metabolites (2021) Vol. 11, Iss. 10, pp. 690-690
Open Access | Times Cited: 181
Genetic association of lipids and lipid-lowering drug target genes with non-alcoholic fatty liver disease
Ziang Li, Bin Zhang, Qing‐Rong Liu, et al.
EBioMedicine (2023) Vol. 90, pp. 104543-104543
Open Access | Times Cited: 78
Insights Into Causal Effects of Genetically Proxied Lipids and Lipid‐Modifying Drug Targets on Cardiometabolic Diseases
Liwan Fu, Qin Liu, Hong Cheng, et al.
Journal of the American Heart Association (2025)
Open Access | Times Cited: 2
Results of Bococizumab, A Monoclonal Antibody Against Proprotein Convertase Subtilisin/Kexin Type 9, from a Randomized, Placebo-Controlled, Dose-Ranging Study in Statin-Treated Subjects With Hypercholesterolemia
Christie M. Ballantyne, Joel Neutel, Anne Cropp, et al.
The American Journal of Cardiology (2015) Vol. 115, Iss. 9, pp. 1212-1221
Open Access | Times Cited: 162
Endogenous Allosteric Modulators of G Protein–Coupled Receptors
Emma T. van der Westhuizen, Céline Valant, Patrick M. Sexton, et al.
Journal of Pharmacology and Experimental Therapeutics (2015) Vol. 353, Iss. 2, pp. 246-260
Open Access | Times Cited: 137
Trajectories of Blood Lipid Concentrations Over the Adult Life Course and Risk of Cardiovascular Disease and All‐Cause Mortality: Observations From the Framingham Study Over 35 Years
Meredith S. Duncan, Ramachandran S. Vasan, Vanessa Xanthakis
Journal of the American Heart Association (2019) Vol. 8, Iss. 11
Open Access | Times Cited: 136
Relevance of Multi-Omics Studies in Cardiovascular Diseases
Paola León‐Mimila, Jessica Wang, Adriana Huertas‐Vázquez
Frontiers in Cardiovascular Medicine (2019) Vol. 6
Open Access | Times Cited: 123
Macrophage Apoptosis and Necrotic Core Development in Atherosclerosis: A Rapidly Advancing Field with Clinical Relevance to Imaging and Therapy
Leticia González, Bernardo L. Trigatti
Canadian Journal of Cardiology (2016) Vol. 33, Iss. 3, pp. 303-312
Closed Access | Times Cited: 118
The effects of a nutraceutical combination on plasma lipids and glucose: A systematic review and meta -analysis of randomized controlled trials
Matteo Pirro, Massimo R. Mannarino, Vanessa Bianconi, et al.
Pharmacological Research (2016) Vol. 110, pp. 76-88
Closed Access | Times Cited: 99
Brothers in Arms: ABCA1- and ABCG1-Mediated Cholesterol Efflux as Promising Targets in Cardiovascular Disease Treatment
Sanne J.C.M. Frambach, Ria de Haas, Jan Smeitink, et al.
Pharmacological Reviews (2019) Vol. 72, Iss. 1, pp. 152-190
Open Access | Times Cited: 99
ABCA1 and ABCG1 as potential therapeutic targets for the prevention of atherosclerosis
Michinori Matsuo
Journal of Pharmacological Sciences (2021) Vol. 148, Iss. 2, pp. 197-203
Open Access | Times Cited: 99
Cardiovascular injury induced by tobacco products: assessment of risk factors and biomarkers of harm. A Tobacco Centers of Regulatory Science compilation
Daniel J. Conklin, Suzaynn F. Schick, Michael J. Blaha, et al.
AJP Heart and Circulatory Physiology (2019) Vol. 316, Iss. 4, pp. H801-H827
Open Access | Times Cited: 85
The Molecular Basis of Predicting Atherosclerotic Cardiovascular Disease Risk
Matthew Nayor, Kemar Brown, Ramachandran S. Vasan
Circulation Research (2021) Vol. 128, Iss. 2, pp. 287-303
Open Access | Times Cited: 76
Plasma proprotein convertase subtilisin/kexin type 9 levels and the risk of first cardiovascular events
Paul M. Ridker, Nader Rifai, Gary Bradwin, et al.
European Heart Journal (2015) Vol. 37, Iss. 6, pp. 554-560
Open Access | Times Cited: 89
Metabolomic Consequences of Genetic Inhibition of PCSK9 Compared With Statin Treatment
Eeva Sliz, Johannes Kettunen, Michael V. Holmes, et al.
Circulation (2018) Vol. 138, Iss. 22, pp. 2499-2512
Open Access | Times Cited: 82
Page 1 - Next Page

Scroll to top